Introduction
============

Podocytes are major components of the glomerular basement membrane with endothelial cells and play key roles in barrier functions.^[@bib1]^ Podocytes are terminally differentiated and highly specialized cells composed of cell bodies, major processes and foot processes interlinked by slit diaphragms.^[@bib2]^ Slit diaphragm proteins are crucial molecular components of the glomerular filtration barrier and are also involved in actin polymerization.^[@bib3],\ [@bib4]^ Foot process effacement can result from slit diaphragm disruption and podocyte injury. Podocyte injury is a primary factor in the development of diabetic nephropathy.^[@bib5]^ Therefore, understanding the mechanisms that control the presence of podocyte-specific slit diaphragm proteins and their involvement in diabetic nephropathy may help to provide better treatment.

Many studies have identified novel slit diaphragm proteins in podocyte foot processes.^[@bib6],\ [@bib7],\ [@bib8],\ [@bib9]^ Nephrin is a structural component of the slit diaphragm formed by neighboring podocytes.^[@bib10],\ [@bib11]^ Podocin is a key factor in the maintenance of slit diaphragm homeostasis.^[@bib10]^ Synaptopodin is a proline-rich protein that is directly related to actin polymerization.^[@bib12]^ Podocalyxin plays an essential role in maintaining an open urinary space by virtue of the physicochemical properties of its highly negatively charged ectodomain.^[@bib13]^ Glucocorticoid-induced transcript 1 (GLCCI1) was first described by Nishibori *et al.*^[@bib14]^ and is expressed at the capillary loop stage of glomerular development. The podocyte-specific proteins nephrin and podocin are also expressed in podocytes at the capillary loop stage.^[@bib15],\ [@bib16]^ GLCCI1, nephrin and podocin have been shown to be simultaneously expressed in podocytes and appear to be activated via the same signaling pathway. In our previous study, we demonstrated that nephrin and podocin expression in the rat glomerulus was regulated by treatment with the phosphoinositide 3-kinase (PI3K) inhibitor wortmannin.^[@bib17]^ The PI3K family of enzymes is involved in cellular functions such as cell growth, proliferation, differentiation and motility.^[@bib18]^ PI3K is also a critical component of the insulin signaling pathway. All PI3Ks are inhibited by wortmannin, a furanosteroid metabolite derived from the fungi *Penicillium funiculosum* and *Talaromyces (Penicillium) wortmannii* and is a specific and covalent inhibitor of PI3Ks. Wortmannin is a common cell biology reagent and has previously been used to inhibit DNA repair, receptor-mediated endocytosis and cell proliferation.^[@bib19]^ Treatment of diabetic nephropathy through the PI3K signaling pathway has recently attracted great interest.^[@bib20],\ [@bib21]^ However, the signaling pathway between GLCCI1 and PI3K in diabetic nephropathy remains unknown. In this study, we demonstrated that GLCCI1 was associated with the PI3K signaling pathway. Serum/glucocorticoid-regulated kinase 1 (SGK1) is activated by PI3K and overexpressed in diabetic nephropathy. Overexpression of SGK1 in diabetic nephropathy inhibits a number of transcription factors, including the cAMP response element-binding protein (CREB) and forkhead box O3 (FOXO3A).^[@bib22]^ Therefore, GLCCI1 expression is predicted to be influenced by transcription factors such as FOXO3A.

Here, we demonstrated that GLCCI1 was a novel podocyte foot process protein that was regulated via the PI3K signaling pathway both *in vivo* and *in vitro*. Moreover, GLCCI1 appeared to be associated with the development of podocyte foot processes because GLCCI1 colocalized with the known podocyte-specific slit diaphragm proteins nephrin and synaptopodin.

Materials and methods
=====================

Cell culture
------------

The E11 podocyte cell line (Cell Line Service, Baden-Wuerttemberg, Germany) was used for this study. Differentiated podocytes were cultured in RPMI-1640 medium (Invitrogen, Waltham, MA, USA) containing 10% fetal bovine serum and penicillin/streptomycin (100 U ml^−1^ and 100 mg ml^−1^, respectively) and incubated at 33 °C in a 5% CO~2~ atmosphere. Podocytes were used between passages 33 and 35. The podocytes were divided into three groups: the normal glucose group (5 m[M D]{.smallcaps}-glucose, control), high glucose group (25 m[M D]{.smallcaps}-glucose, diabetes) and wortmannin-treated diabetic group (25 m[M D]{.smallcaps}-glucose+0.32 μ[M]{.smallcaps} wortmannin). Podocytes from the three groups were incubated in culture medium containing either 5 or 25 m[M]{.smallcaps} glucose for 24 h. After 24 h of incubation, the wortmannin group incubated with high glucose was treated with wortmannin (0.32 μ[M]{.smallcaps}, LC Laboratories, Woburn, MA, USA); the half-maximal inhibitory concentration of wortmannin was determined by CCK-8 assay (data not shown). At 24 h after treatment with wortmannin, RNA and proteins were extracted from the podocytes.

Animals
-------

All animal procedures were performed according to the guidelines provided by the Committee of Animal Ethics at Korea University. Fifteen healthy male 4-week-old Sprague Dawley rats (Orient, Technical Corporation of Charles River Technology, Gapyoung, Korea) weighing 150±10 g were randomly divided into 3 groups: the control, diabetic and wortmannin-treated diabetic groups (*n*=5 for each group). Before the experiments, the rats were allowed 1 week to adapt to the laboratory conditions. The rats were maintained under standard conditions with a 12 h/12 h light/dark cycle at 23±1 °C and 50±10% humidity. All animals had free access to water. All animals in the diabetic and wortmannin-treated diabetic groups were intraperitoneally injected with 65 mg kg^−1^ body weight streptozotocin (STZ; Sigma-Aldrich, St Louis, MO, USA) dissolved in pH 4.5 sodium citrate buffer. Control rats were injected with an equivalent volume of sodium citrate buffer. At 3 days after STZ injection, the animals were considered to be diabetic if the plasma glucose levels were ⩾300 mg dl^−1^.^[@bib23]^ Wortmannin (1 mg kg^−1^, LC Laboratories) was dissolved in dimethyl sulfoxide and intraperitoneally injected every day for 8 weeks. The control and diabetic group rats were injected with an equivalent volume of dimethyl sulfoxide. All rats were killed after 8 weeks.^[@bib17]^

Reverse transcription-PCR
-------------------------

Total RNA was extracted from all specimens (podocytes and Sprague Dawley rats) using the TRIzol reagent (Invitrogen) and reversed transcribed using the SuperScript III reverse transcriptase (Invitrogen).^[@bib24]^ The sequences of the primers used are as follows: GLCCI1 sense 5′-GCCTTCACCAGTGAAATGACAA-3′ and antisense 5′-TTCCTGACCACTTACTGTCCCA-3′ Nephrin sense 5′-GTTCAGCTGGGAGAGACTGG-3′ and antisense 5′-AATCGGACGACAAGACGAAC-3′ Podocin sense 5′-TCTCCCAAACCTGTTGAACC-3′ and antisense 5′-GCGTGTGTCCATCTTGTGAC-3′ Synaptopodin sense 5′-GCAGAGGAAGTGAGGTCCAG-3′ and antisense 5′-GATGCCACTAGGGTGCTAGG-3′ Podocalxyin sense 5′-GGTGGCAGTGAAGAGATTC-3′ and antisense 5′-CTGTGAGTCGTTGTTGGTC-3′ and GAPDH sense 5′-CTCTACCCACGGCAAGTTCAA-3′ and antisense 5′-GGATGACCTTGCCCACAGC-3′. The PCR products were visualized on 1.5% agarose gels, and the band density was measured using the Gel-Doc image analysis system 2000 (Bio-Rad, Hercules, CA, USA).

Western blotting analysis
-------------------------

For western blotting, cell lysates of podocytes and rat kidneys were extracted with RIPA buffer (Sigma) containing a protease inhibitor cocktail. Protein concentrations were determined using the Bradford assay method.^[@bib25]^ For immunoblotting, the extracted protein samples were separated by SDS--polyacrylamide gel electrophoresis and then transferred to nitrocellulose membranes. The membranes were incubated with blocking solution containing a 1:1000 dilution of the rabbit anti-GLCCI1 antibody (ab107491, Abcam, Cambridge, UK), a 1:500 dilution of the goat anti-nephrin antibody (sc-19000, Santa Cruz Biotechnology, Santa Cruz, CA, USA), a 1:500 dilution of the rabbit anti-podocin antibody (sc-21009, Santa Cruz Biotechnology), a 1:1000 dilution of the rabbit anti-SGK1 antibody (ab59337, Abcam) or a 1:1000 dilution of the rabbit anti-FOXO3A antibody (ab47285, Abcam).The membranes were then incubated with blocking solution containing 1:1000 (for GLCCI1, podocin, SGK1 and FOXO3A) dilutions of a horseradish peroxidase-conjugated goat anti-rabbit IgG secondary antibody (1858415, Pierce Biotechnology, Waltham, MA, USA) or a 1:1000 (for nephrin) dilution of a horseradish peroxidase-conjugated donkey anti-goat IgG secondary antibody (ab6885, Abcam). The reactive bands were detected by chemiluminescence using an enhanced chemiluminescence (ECL) system (Millipore, Billerica, MA, USA). Gel bands were scanned with the luminescent image analyzer LAS-3000 and analyzed using the Multi Gauge image analysis software (Fuji Film, Tokyo, Japan).^[@bib26],\ [@bib27]^

Immunofluorescence
------------------

For the immunofluorescence assay, podocytes and rat kidneys were fixed in 4% paraformaldehyde. The kidneys were cut into 5 μm sections. The cryosections were deparaffinized with xylene and rehydrated using a graded ethanol series. The podocyte cells and kidney sections were blocked with 1% bovine serum albumin for 1 h, incubated with primary antibodies for 1 h at room temperature in a humidified chamber, and then incubated with a donkey anti-goat 488-conjugated secondary antibody (ab150129, Abcam) or goat anti-rabbit 568-conjugated secondary antibody (ab175471, Abcam) at room temperature for 1 h. The following antibodies were used: rabbit anti-GLCCI1 (1:100, ab107491, Abcam), goat anti-nephrin (1:100, sc-19000, Santa Cruz Biotechnology), rabbit anti-podocin (1:100, sc-21009, Santa Cruz Biotechnology), goat anti-synaptopodin (1:100, sc-21536, Santa Cruz Biotechnology), rabbit anti-SGK1 (1:100, ab59337, Abcam) and rabbit anti-FOXO3A (1:100, ab47285, Abcam). All images were obtained using a Carl-Zeiss LSM 700 confocal microscope (Carl-Zeiss, Jena, Germany).

Immunoelectron microscopy
-------------------------

For immunoelectron microscopy, rat kidney cortex samples were fixed in a solution containing phosphate-buffered 4% paraformaldehyde (EM grade) and 2.3 [M]{.smallcaps} sucrose overnight. Immunoelectron microscopy was performed according to the method described by Tokuyasu.^[@bib28]^ In the immunogold labeling experiment, a goat anti-rabbit antibody (gold particles, 10 nm, Abcam) was used to detect GLCCI1. Electron microscopy images were obtained using a Tecnai F20 transmission electron microscope (Don R.Kania, Hillsboro, OR, USA).

Statistical analysis
--------------------

All results are expressed as the means±s.e.m. Comparison of continuous variables between more than two groups was performed using a one-way ANOVA, and Fisher\'s least significant difference test was used to assess differences between groups. *P*\<0.05 was considered statistically significant. The SPSS software package V12.0 (Chicago, IL, USA) was used for all statistical analyses.

Results
=======

GLCCI1 is highly specific for the glomerulus and podocyte foot processes and its expression is regulated via the PI3K signaling pathway
---------------------------------------------------------------------------------------------------------------------------------------

The presence of GLCCI1 transcripts in podocytes and rat kidneys was confirmed by reverse transcription-PCR and western blotting. To induce diabetic nephropathy conditions *in vitro* and *in vivo*, we used an appropriate high glucose (25 m[M]{.smallcaps}) medium for the culture of podocytes and treated the animals with STZ. At the RNA level, the intensity of the GLCCI1 transcripts was clearly stronger in the normal glucose (5 m[M]{.smallcaps}) group of podocytes and the control group of rats. In contrast, a very weak signal was detected in the high glucose-induced podocytes and STZ-induced diabetic rats. The expression of podocyte-specific markers such as nephrin, podocin, synaptopodin and podocalyxin was similar to GLCCI1 ([Figures 1a and b](#fig1){ref-type="fig"}). We also investigated the recovery of GLCCI1 and podocyte-specific proteins at the RNA level following treatment with wortmannin. A CCK-8 assay was used to determine the appropriate wortmannin concentration (0.32 μ[M]{.smallcaps}) for administration to podocytes. In addition, we administered wortmannin to the Sprague Dawley rats at a dosage of 1 mg kg^−1^. *In vitro*, a higher-intensity GLCCI1 band was observed in the wortmannin-treated diabetic group, whereas significantly decreased GLCCI1 expression was observed in the high glucose group. Wortmannin promotes GLCCI1 recovery via the PI3K pathway in diabetic nephropathy. Podocyte-specific markers showed expression patterns similar to GLCCI1 in the reverse transcription-PCR ([Figure 1a](#fig1){ref-type="fig"}). In addition, we examined whether the GLCCI1 RNA levels were regulated by wortmannin treatment in rat kidneys. GLCCI1 expression in the rat kidneys was regulated by wortmannin treatment. Expression of the podocyte-specific markers nephrin, podocin, synaptopodin and podocalyxin was also recovered in the rat kidneys by wortmannin treatment. GLCCI1 and the podocyte-specific markers showed similar signaling patterns *in vivo* ([Figure 1b](#fig1){ref-type="fig"}).

At the protein level, the GLCCI1 (58 kDa) expression levels differed significantly between the control and diabetic podocytes and rat kidneys. Treatment with wortmannin decreased GLCCI1 expression in the diabetic group ([Figures 2a and b](#fig2){ref-type="fig"}). In the podocytes, nephrin and podocin showed an expression pattern similar to GLCCI1. The expression of the podocyte-specific markers nephrin and podocin was confirmed in our previous animal study.^[@bib17]^ Nephrin and podocin showed a signaling pattern similar to GLCCI1 *in vivo*. The expression of proteins related to the PI3K pathway was confirmed by western blotting. The SGK1 (55 kDa) and FOXO3A (67 and 105 kDa) expression levels were significantly different between the 5 and 25 m[M]{.smallcaps} groups of podocytes ([Figure 2a](#fig2){ref-type="fig"}). SGK1 is a downstream factor of PI3K that is overexpressed in diabetic nephropathy and regulates a number of transcription factors, such as FOXO3A.^[@bib22]^ SGK1 was overexpressed in the 25 m[M]{.smallcaps} group and was downregulated by treatment with wortmannin. FOXO3A expression, which was blocked by the overexpression of SGK1 in the 25 m[M]{.smallcaps} group, was also regulated by wortmannin. Finally, GLCCI1 expression was regulated by the increased FOXO3A expression in the wortmannin-treated diabetic group. All of the results demonstrated statistical significance by the SPSS software ([Figures 1c, d](#fig1){ref-type="fig"} and [2c, d](#fig2){ref-type="fig"}).

Taken together, these results demonstrated that GLCCI1 was expressed with nephrin, podocin, synaptopodin and podocalyxin *in vivo* and *in vitro* and that GLCCI1 was regulated by a signaling pathway associated with PI3K in diabetic nephropathy.

Localization of GLCCI1 in cultured podocytes and rat glomeruli
--------------------------------------------------------------

We investigated the localization of GLCCI1 in cultured podocytes and rat glomeruli via immunofluorescence. Immunofluorescent staining with an anti-GLCCI1 antibody (Alexa Fluor 568, red, Alan Hirzel, Cambridge, MA, USA) revealed intense reactivity in cultured podocytes and rat glomeruli. In the 25 m[M]{.smallcaps} group of podocytes and the diabetic group of animals, very weak reactivity was observed in contrast to the wortmannin-treated diabetic group ([Figures 3a](#fig3){ref-type="fig"} and [4a](#fig4){ref-type="fig"}). GLCCI1 was localized in the cultured podocytes and rat glomeruli. Therefore, the localization of podocyte-specific markers was examined to determine similarities with GLCCI1. Nephrin (Alexa Fluor 488, green), podocin (Alexa Fluor 568, red) and synaptopodin (Alexa Fluor 488, green) showed patterns of reactivity similar to GLCCI1 ([Figures 3b--d](#fig3){ref-type="fig"} and [4b--d](#fig4){ref-type="fig"}). As shown in [Figures 3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"}, wortmannin ameliorated the weak reactivity observed in the disease conditions. Using immunofluorescence, we also confirmed that SGK1 (Alexa Fluor 568, red) and FOXO3A (Alexa Fluor 568, red) were associated with the PI3K pathway. SGK1 was observed only in the 25 m[M]{.smallcaps} group of podocytes and the diabetic group of animals ([Figures 3e](#fig3){ref-type="fig"} and [4e](#fig4){ref-type="fig"}). Because SGK1 was overexpressed in diabetic nephropathy, it was not observed in the control and wortmannin-treated diabetic groups *in vitro* and *in vivo*. In contrast, FOXO3A was observed only in the control and wortmannin-treated diabetic groups. No FOXO3A reactivity was observed in the 25 m[M]{.smallcaps} group of podocytes and the diabetic group of animals ([Figures 3f](#fig3){ref-type="fig"} and [4f](#fig4){ref-type="fig"}). Because FOXO3A is a transcription factor, its activation is associated with translocation to the nucleus. Thus, FOXO3A must affect the expression and localization of GLCCI1 through the PI3K pathway.

These findings suggest that GLCCI1 is localized with podocyte-specific markers in cultured podocytes and rat glomeruli and that GLCCI1 is regulated by SGK1 and FOXO3A via the PI3K pathway in diabetic nephropathy.

GLCCI1 colocalizes with nephrin and synaptopodin
------------------------------------------------

We performed double-labeling immunofluorescence to examine the overlap between GLCCI1 and the podocyte-specific markers nephrin and synaptopodin in cultured podocytes and rat glomeruli. GLCCI1 colocalized with nephrin and synaptopodin in the cultured podocytes. Merged images showed that the GLCCI1 staining pattern completely overlapped with nephrin and synaptopodin in the cultured podocytes ([Figures 5a and b](#fig5){ref-type="fig"}). GLCCI1 also colocalized with nephrin and synaptopodin in the kidney glomeruli; indeed, the localization of GLCCI1 showed a complete overlap with nephrin and synaptopodin in the rat glomeruli ([Figures 5c and d](#fig5){ref-type="fig"}). In the 25 m[M]{.smallcaps} and diabetic groups, no reactivity of GLCCI1 with nephrin and synaptopodin was observed, whereas increased reactivity of GLCCI1 with nephrin and synaptopodin was observed following treatment with wortmannin.

These data show that GLCCI1, nephrin and synaptopodin are simultaneously regulated via the PI3K pathway. Nephrin is present in foot processes;^[@bib15]^ therefore, GLCCI1 must also be present in foot processes. It is important to note that GLCCI1 is involved in process development.

GLCCI1 expression in the foot processes of rat glomeruli
--------------------------------------------------------

To clarify whether GLCCI1 was expressed and localized in the foot processes of podocytes, rat glomeruli were examined using electron microscopy. Electron microscopic examination of kidneys from the control group rats revealed the complete foot process morphology ([Figure 6a](#fig6){ref-type="fig"}). In the STZ-induced diabetic rats, effacement of the foot processes was observed because of podocyte injury by STZ ([Figure 6b](#fig6){ref-type="fig"}). The morphology of the disrupted foot processes in the diabetic group was recovered by wortmannin treatment ([Figure 6c](#fig6){ref-type="fig"}). In the immunoelectron microscopy images, the GLCCI1 label was detected in the podocyte foot processes in the control group ([Figure 6d](#fig6){ref-type="fig"}). In contrast, GLCCI1 was absent from the podocyte foot processes in the glomeruli from the diabetic group ([Figure 6e](#fig6){ref-type="fig"}). Administration of wortmannin increased GLCCI1 expression in the podocyte foot processes of the glomerulus via the PI3K pathway ([Figure 6f](#fig6){ref-type="fig"}). The quantitation of foot processes and gold-labeled GLCCI1 showed that the expression was significantly decreased in rats with STZ-induced diabetes, whereas the foot processes and gold-labeled GLCCI1 was restored in the wortmannin-treated rats compared with the controls ([Table 1](#tbl1){ref-type="table"}). The electron microscopy analyses demonstrated that GLCCI1 was expressed in podocyte foot processes via the PI3K pathway.

Discussion
==========

GLCCI1 expression has been detected in diverse tissues, including kidney glomeruli.^[@bib14]^ However, the signaling pathway associated with GLCCI1 expression in kidney podocytes remains unknown. In this study, we demonstrated for the first time that GLCCI1 was specifically expressed in podocyte foot processes via the PI3K pathway *in vivo* and *in vitro*. To explore the regulation of GLCCI1 under hyperglycemic conditions, we used two models for *in vitro* and *in vivo* studies: a high glucose-induced podocyte cell line and STZ-induced rats, respectively. In all specimens, GLCCI1 was expressed exclusively in the control and wortmannin-treated diabetic groups and was regulated by the PI3K pathway. A similar expression pattern was observed for podocyte-specific proteins such as nephrin, podocin, synaptopodin and podocalyxin that are important for the glomerular filtration barrier. We investigated changes in the protein expression of GLCCI1, SGK1 and FOXO3A, which are associated with the PI3K pathway, in the cultured podocytes. SGK1 is activated by PI3K and overexpressed in diabetic nephropathy.^[@bib22]^ In addition, SGK1 regulates a number of transcription factors such as CREB and FOXO3A. FOXO3A was highly expressed in the wortmannin-treated diabetic group of podocytes and was accompanied by the downregulation of SGK1 in the wortmannin-treated diabetic group. This signaling pathway can induce GLCCI1 expression because GLCCI1 is a transcript protein. However, our data showed that the podocyte-specific markers nephrin and podocin (but not a transcript protein) showed expression patterns similar to GLCCI1 and were also regulated via the PI3K pathway. This finding indicates that GLCCI1 and the podocyte-specific proteins nephrin, podocin, synaptopodin and podocalyxin are coregulated via the PI3K pathway.

In this study, we confirmed that GLCC1 was localized to podocytes and rat glomeruli similar to other podocyte-specific proteins (nephrin, podocin, synatopodin and podocalyxin). In contrast, extremely low reactivity of GLCCI1 and podocyte-specific proteins was detected under hyperglycemic conditions. In addition, both podocyte-specific proteins and GLCC1 were found to be regulated by treatment with wortmannin. Colocalization of SGK1 and FOXO3A, which are associated with the PI3K signaling pathway, was also observed *in vivo* and *in vitro*. This result supports the hypothesis that GLCCI1 is localized in the podocyte and rat glomerulus and that its localization is related to PI3K signaling.

In the colocalization studies, the GLCCI1 expression pattern showed a complete overlap with the podocyte-specific proteins nephrin and synaptopodin in the 5 m[M]{.smallcaps} group of cultured podocytes and the control group of rat glomeruli. No reactivity was observed in the 25 m[M]{.smallcaps} group of cultured podocytes and the diabetic group of rat glomeruli. Wortmannin increased the reactivity of GLCCI1 and the podocyte-specific proteins nephrin and synaptopodin *in vivo* and *in vitro*. GLCCI1 was found to be regulated simultaneously with nephrin and synaptopodin. Nephrin is a key factor in the glomerular slit diaphragm.^[@bib29]^ The absence of nephrin leads to proteinuria and foot process effacement.^[@bib30]^ GLCCI1 deficiency also leads to proteinuria.^[@bib14]^ Synaptopodin is essential for the integrity of the podocyte actin cytoskeleton and the regulation of podocyte cell migration.^[@bib31]^ Synaptopodin protects against proteinuria in kidney podocytes.^[@bib32]^ Thus, GLCCI1 in addition to nephrin and synaptopodin is a major factor in podocyte foot process functions.

The immunoelectron microscopy results showed a significant decrease in GLCCI1 expression and foot process effacement in rats in the diabetic group. Moreover, we directly confirmed the expression and localization of GLCCI1 in podocyte foot processes and the glomerular basement membrane by treatment with wortmannin. Foot process effacement was not detected following wortmannin treatment in the diabetic group. Wortmannin may regulate foot process effacement and decrease GLCCI1 in the diabetic group. This result indicates that GLCCI1 is related to the PI3K signaling pathway in podocytes.

In conclusion, we identified GLCCI1 as a novel podocyte foot process protein that was regulated via the PI3K pathway. GLCCI1 colocalizes with nephrin and synaptopodin that are known podocyte slit diaphragm proteins. GLCCI1 may play an important role in the proper formation of foot processes in podocytes. The presence of GLCCI1 in association with the PI3K signaling pathway may contribute to development and maintenance of podocyte structure and function.
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![Detection of glucocorticoid-induced transcript 1 (GLCCI1) and podocyte-specific marker gene expression by reverse transcription-PCR (RT-PCR). (**a**) Expression of the genes encoding GLCCI1, nephrin, podocin, synaptopodin and podocalyxin showed similar patterns in the podocytes. The expression levels differed significantly between the high glucose-induced and wortmannin-treated diabetic groups of podocytes. (**b**) The expression of the genes encoding GLCCI1, nephrin, podocin, synaptopodin and podocalyxin showed similar patterns in the kidneys of diabetic rats. In addition, wortmannin ameliorated the expression of all podocyte-specific proteins including GLCCI1. (**c**, **d**) The relative band intensity of proteins in podocytes and the kidneys of diabetic rats was observed by RT-PCR. The band intensity was measured using the Multi Gauge V3.0 software (Fuji Film). \*\*\**P*\<0.001, 5 m[M]{.smallcaps} (control) and wortmannin-treated diabetic groups versus the high glucose--induced group by analysis of variance (ANOVA; means±s.e.m., *n*=3).](emm201628f1){#fig1}

![Analysis of glucocorticoid-induced transcript 1 (GLCCI1) protein expression and involvement in the phosphoinositide 3-kinase (PI3K) pathway by western blotting. (**a**) GLCCI1, nephrin and podocin were expressed only in the 5 m[M]{.smallcaps} and the wortmannin-treated diabetic groups. Serum/glucocorticoid-regulated kinase 1 (SGK1) was expressed only in the high glucose-induced group. Forkhead box O3 (FOXO3A) was regulated by wortmannin. (**b**) GLCCI1 was expressed only in the control and wortmannin-treated diabetic groups. GLCCI1 was significantly decreased in the diabetic group. (**c**, **d**) The relative band intensities of proteins in the podocytes and the kidneys of diabetic rats were observed by western blot analysis. The band intensities were measured using the Multi Gauge V3.0 software (Fuji Film). \*\*\**P*\<0.001, 5 m[M]{.smallcaps} (control) and wortmannin-treated diabetic groups versus the 25 m[M]{.smallcaps} (diabetes) group by analysis of variance (ANOVA; means±s.e.m., *n*=3).](emm201628f2){#fig2}

![The localization of glucocorticoid-induced transcript 1 (GLCCI1), podocyte-specific markers and proteins involved in the phosphoinositide 3-kinase (PI3K) signaling pathway in podocytes. (**a**) In podocytes, GLCCI1 (red, Alexa 568 conjugated) was localized in the 4\',6-diamidino-2-phenylindole (DAPI)-stained nuclei. No GLCCI1 localization was observed in the 25 m[M D]{.smallcaps}-glucose-treated podocytes. However, GLCCI1 was regulated by wortmannin treatment. (**b**--**d**) The podocyte-specific proteins nephrin (green, Alexa 488 conjugated), podocin (red) and synaptopodin (green) showed a reactivity pattern similar to GLCCI1 in podocytes treated with wortmannin. (**e**) Serum/glucocorticoid-regulated kinase 1 (SGK1; red) was observed only in the 25 m[M]{.smallcaps} group. We confirmed that treatment with wortmannin decreased SGK1 expression. (**f**) Forkhead box O3 (FOXO3A; red) was observed in the 5 m[M]{.smallcaps} group. A lower FOXO3A signal was accompanied by high reactivity of SGK1 in the 25 m[M]{.smallcaps} group. Localization of FOXO3A was regulated by treatment with wortmannin. Original magnification: × 400. Scale bar, 50 μm.](emm201628f3){#fig3}

![The localization of glucocorticoid-induced transcript 1 (GLCCI1), podocyte-specific markers and proteins associated with the phosphoinositide 3-kinase (PI3K) signaling pathway in the rat glomerulus. (**a**) Staining of rat kidney sections with an antibody against GLCCI1 (red) is shown. The diabetic group showed low reactivity. However, GLCCI1 was regulated by wortmannin treatment. (**b**--**d**) The podocyte-specific proteins nephrin (green), podocin (red) and synaptopodin (green) showed a reactivity pattern similar to GLCCI1 following wortmannin treatment. (**e**) Serum/glucocorticoid-regulated kinase 1 (SGK1; red) was observed only in the diabetic group. We confirmed that SGK1 expression was decreased by wortmannin. (**f**) Forkhead box O3 (FOXO3A; red) was observed in the control group. The lower reactivity of FOXO3A was accompanied by the overexpression of SGK1 in the diabetic group. The localization of FOXO3A was regulated by wortmannin treatment. Original magnification: × 400. Scale bar, 50 μm.](emm201628f4){#fig4}

![Colocalization of glucocorticoid-induced transcript 1 (GLCCI1) with the podocyte-specific proteins nephrin and synaptopodin. (**a**) Double labeling with the podocyte-specific marker nephrin (green) showed a complete overlap (merge, yellow) with the distribution of GLCCI1 (red) in the 5 m[M]{.smallcaps} and wortmannin-treated diabetic groups of cultured podocytes. (**b**) GLCCI1 (red) also colocalized with synaptopodin (green). We observed overlapping reactivity (yellow indicates red plus green) in the 5 m[M]{.smallcaps} and wortmannin-treated diabetic groups of cultured podocytes. (**c**, **d**) In rat glomeruli, we observed overlapping reactivity (yellow) via the colocalization of GLCCI1 (red) with nephrin and synaptopodin (green). Wortmannin ameliorated the lower reactivity in glomeruli from rats in the diabetic group. Original magnification: × 400. Scale bar, 50 μm.](emm201628f5){#fig5}

![Localization of glucocorticoid-induced transcript 1 (GLCCI1) in podocyte foot processes (FPs) by immunoelectron microscopy. (**a**) FPs formed by normal podocytes in the control group. (**b**) Effacement of FPs by podocyte injury in the diabetic group. Podocytes were disrupted by streptozotocin (STZ) treatment. (**c**) Podocyte FPs were regulated around the glomerular basement membrane (GBM) by treatment with wortmannin. Wortmannin could restore podocytes to their original condition. (**d**) Immunogold particles (arrowheads) marking GLCCI1 (10 nm gold) were observed in podocyte FPs of the control group. (**e**) No labeling was observed in podocyte FPs of the diabetic group. (**f**) Localization of GLCCI1 in podocyte FPs was observed in the wortmannin-treated diabetic group. Scale bar, 200 nm.](emm201628f6){#fig6}

###### Summary of quantitative immunoelectron microscopy data

  *Group*      *FP number per μm*   *Gold particle per μm*^*2*^
  ------------ -------------------- -----------------------------
  Control      8.5±0.6              30.3±4.3
  Diabetes     0.3±0.2\*\*\*        2.5±0.8\*\*\*
  Wortmannin   6.9±0.5              19.7±3.9

Abbreviation: FP, foot process.

The quantitation of foot process formation (foot process number per μm) and the gold labeling intensity of glucocorticoid-induced transcript 1 (GLCCI1; gold particle per μm^2^) are shown.

\*\*\**P*\<0.001, control and wortmannin-treated diabetic groups versus the diabetes group by analysis of variance (ANOVA; means±s.e.m., *n*=3).
